# Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT03717012** · PHASE4 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 19 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Nintedanib
- **OTHER:** Pulmonary rehabilitation program

## Key facts

- **NCT ID:** NCT03717012
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-15
- **Primary completion:** 2020-03-27
- **Final completion:** 2020-06-10
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** The trial was terminated prematurely due to difficulties with recruitment because of the COVID-19 pandemic.
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03717012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03717012, "Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03717012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*